Comparative Pharmacology
Head-to-head clinical analysis: LIMBITROL DS versus LORAZEPAM INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIMBITROL DS versus LORAZEPAM INTENSOL.
LIMBITROL DS vs LORAZEPAM INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Limbitrol DS is a combination of amitriptyline (a tricyclic antidepressant) and chlordiazepoxide (a benzodiazepine). Amitriptyline inhibits the reuptake of serotonin and norepinephrine, enhancing neurotransmission in the CNS. Chlordiazepoxide binds to GABA-A receptors, potentiating GABAergic inhibitory effects, leading to anxiolytic and sedative effects.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
1 tablet (amitriptyline 25 mg/chlordiazepoxide 10 mg) orally 3 times daily initially, gradually increasing to 2 tablets orally 3 times daily or 3 tablets orally twice daily if needed; maximum 6 tablets per day.
0.5-2 mg orally every 6-8 hours as needed. Maximum 4 mg/day.
None Documented
None Documented
Chlordiazepoxide: 5-30 hours (parent drug), active metabolite (desmethylchlordiazepoxide) 10-30 hours; amitriptyline: 13-36 hours (parent), nortriptyline (active metabolite) 18-44 hours. Half-lives increase with age and hepatic impairment.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in elderly (15-20 hours) and patients with hepatic impairment (up to 30-40 hours).
Renal: 70-80% as conjugated metabolites, <5% unchanged; fecal: 10-20% via biliary excretion.
Renal excretion of glucuronide conjugates; <1% unchanged drug excreted renally. Fecal elimination accounts for approximately 10% of administered dose.
Category C
Category D/X
Benzodiazepine/Tricyclic Antidepressant Combination
Benzodiazepine